← Back to Search

Electronic Alerts for Heart Failure Prevention in Type 2 Diabetes

N/A

Waitlist Available

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial is testing whether a clinical decision support tool can help improve heart failure risk stratification in patients with type 2 diabetes.

Who is the study for?

This trial is for healthcare providers in general internal medicine, subspecialty internal medicine, and family medicine outpatient clinics. It's not for those who see patients with heart failure or already on SGLT-2i medications during hospital stays.Check my eligibility

What is being tested?

The study tests an on-screen alert system designed to help doctors better identify the risk of heart failure in patients with type 2 diabetes. The goal is to increase the prescription of beneficial drugs like SGLT2 inhibitors.See study design

What are the potential side effects?

Since this trial involves an electronic alert system rather than a medication, there are no direct side effects for patients. However, there may be indirect impacts on patient care based on how providers respond to alerts.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Frequency of prescription of SGLT-2i medication at outpatient clinic visits

Secondary outcome measures

Adherence of prescription of SGLT-2i medication at outpatient clinic visit

Other outcome measures

Frequency of incident HF

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Electronic AlertExperimental Treatment1 Intervention

Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of HF in diabetes and the lack of an active order for SGLT2i therapy.

Group II: No AlertActive Control1 Intervention

The CDS will not issue an on-screen alert.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

On-screen electronic alert

2018

N/A

~800

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,047 Previous Clinical Trials

1,052,299 Total Patients Enrolled

23 Trials studying Heart Failure

11,839 Patients Enrolled for Heart Failure

Media Library

On-screen electronic alert Clinical Trial Eligibility Overview. Trial Name: NCT04791826 — N/A

Heart Failure Research Study Groups: Electronic Alert, No Alert

Heart Failure Clinical Trial 2023: On-screen electronic alert Highlights & Side Effects. Trial Name: NCT04791826 — N/A

On-screen electronic alert 2023 Treatment Timeline for Medical Study. Trial Name: NCT04791826 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have been recruited for this trial?

"Affirmative. According to clinicaltrials.gov, this medical investigation is actively recruiting participants and was first posted on March 25th 2021 before being updated most recently on November 30th 2022. Its ambition of 1500 individuals needs to be accomplished by 1 research centre."

Answered by AI

Does this medical experiment have any openings for participants?

"Affirmative. Clinicaltrials.gov reports that this experiment, which was published on March 25th 2021, is currently recruiting patients. 1500 participants must be gathered at a single site for the trial to proceed."

Answered by AI